Sensorion SA (EPA:ALSEN)

France flag France · Delayed Price · Currency is EUR
0.4000
+0.0276 (7.41%)
Apr 30, 2025, 5:35 PM CET
-43.34%
Market Cap 120.20M
Revenue (ttm) 6.65M
Net Income (ttm) -25.97M
Shares Out 300.49M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,104,740
Average Volume 956,495
Open 0.4069
Previous Close 0.3724
Day's Range 0.3905 - 0.4915
52-Week Range 0.1544 - 0.9700
Beta 1.30
RSI 52.40
Earnings Date Jun 18, 2025

About Sensorion

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company’s product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2a clinical which is an orally available small molecule protecting and preserving inner ear tissue from damage, responsible for hearing ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 63
Stock Exchange Euronext Paris
Ticker Symbol ALSEN
Full Company Profile

Financial Performance

In 2024, Sensorion's revenue was 6.65 million, an increase of 16.76% compared to the previous year's 5.70 million. Losses were -25.97 million, 17.7% more than in 2023.

Financial Statements

News

Sensorion reports FY results

6 weeks ago - Seeking Alpha